British pharmaceutical giant AstraZeneca on Monday said an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus. Pascal Soriot, CEO of AstraZeneca, said the development marked an “important milestone” in the fight against the global health crisis. “This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” said. AstraZeneca’s shares closed 2,35% higher on Friday, at $55,30.